albumin is a plasmatic protein that is highly sensitive to post-translational modifications (PTMs), such as glycation.
Non-enzymatic glycation is indeed one of the underlying modifications that can modify its native secondary and tertiary structure [3] . In this process, also known as the Maillard reaction, free amine groups of albumin are initially attached by glucose or derivatives to reversibly form a Schiff base product, followed by the formation of a stable fructosamine residue by Amadori rearrangement. This is the early glycation process: Schiff's base and fructosamine (Amadori product) have been called early glycation adducts. Further modifications in these early stage glycation products, such as rearrangement, oxidation, polymerization, and cleavage give rise to irreversible conjugates, called advanced glycation end products (AGEs) [4] .
Non-enzymatic glycation occurs in normal conditions, but HSA is typically 2-3 times more glycated than the rest of the serum proteins in hyperglycaemic condition [3] .
Several in vitro studies have shown the implication of glycated albumin, mainly AGE-albumin, in cardiovascular diseases (CVD): for example, platelets are activated by both irreversibly and reversibly glycated albumin, thus promoting CVD development [5] ; in endothelial cells glycated albumin enhanced ROS production by activating multiple signaling pathways [6] . Glycated albumin can also trigger damaging effects in vitro and in vivo on hepatic cells [7] , all features that contribute to the increased mortality of diabetic patients [8] . Finally, bovine glycated albumin stimulates cardiomyocyte ROS production, which results in NF-κB activation and upregulation of atrial natriuretic factor mRNA suggesting that glycated albumin may play a role in the development of diabetic heart disease [9] .
The relationship between AGEs and cardiovascular diseases is well known [10] . Elevated levels of AGEs were first associated with diabetes, where it was thought that AGEs formation was exclusively the result of increased blood sugar concentrations [11] . However, recent studies have extended this view and have shown that AGEs accumulation occurs also in pathological situations such as cardiac dysfunction, and renal failure, independent of diabetes [12] [13] [14] [15] .
Further, through decreased compliance of the heart and the vasculature, AGE accumulation is considered to be related to the onset and progression of heart failure (HF) [14, 16] .
However, the possible effects of early glycation products, such as the Amadori product, in the cardiovascular system have been less studied than the effects of the irreversible AGEs.
In this study we analyzed the levels of the Amadori product glycated-albumin (GA) in non-diabetic patients with HF and the effects of this modified protein on cardiomyocytes in vitro.
Materials and methods

Study population
Plasma samples were obtained from a subset of healthy subjects (controls) and HF patients matched according to their age, sex, and clinical characteristics, from a previously enrolled population [17] . The study was approved by the Ethical Committee European Institute of Oncology and Monzino Cardiologic Center (registration number R205-CCFM S208/412) [17] . All patients belong to a cohort of HF patients regularly followed at our HF Unit and underwent our standard HF assessment which included full clinical evaluation, standard laboratory tests, echocardiography, spirometry, and alveolar capillary diffusion, as well as cardiopulmonary exercise test. All patients had severe HF, being in New York Heart Association (NYHA) class III and IV, but were in stable clinical conditions. Patients with an established diagnosis of diabetes mellitus or under diabetes treatment were excluded. A detailed summary of the clinical characteristics, obtained as previously described [17] , is reported in Table 1 .
Quantitation of glycated albumin (GA) by mass spectrometry
The relative composition of albumin isoforms in human plasma samples was evaluated, as previously described [18] , by direct infusion using the Xevo TQS micro triple quadrupole mass spectrometer coupled with the M-Class UPLC system (Waters Corporation, Milford, USA). Briefly, centrifuged plasma samples at 3000×g for 10 min at 4°C were diluted 200 folds in 50% ACN containing 0.1% FA. After centrifugation at 14 000×g for 10 min at 4°C, 5 μl were injected at 5 μl/min and the spectra were acquired for 6 min with the following parameters: positive ESI mode; mass range 1100-1350 m/z; capillary voltage, 3 kV; cone, 90 V; desolvation temperature 350°C; source temperature 150°C. Data processing for deconvolution was performed with the MaxEnt1 function on the Masslynx software (Waters Corporation, Milford, USA). Mercaptoalbumin (native HSA) and GA (+160 ± 2 Da) were detected and their intensities were used to calculate the relative abundances as previously described [18] and detailed in Supplementary information.
Carboxymethyl lysine assay
Plasma levels of carboxymethyl lysine (CML) were measured with a commercially available ELISA kit (Biosite, Taby, Sweden) according to the manufacturer's instruction.
Cell culture and treatment
The HL-1 cardiomyocytes, a kind gift of Prof. W.C. Claycomb, (LSU Health Sciences Center, New Orleans, LA, USA), were cultured in complete Claycomb medium supplemented with 10% FBS (Sigma-Aldrich, Milan, Italy), 2 mmol/L L-glutamine (Thermo Fisher Scientific, Milan, Italy), and 100 μmol/L norepinephrine (Sigma-Aldrich, Milan, Italy) according to Prof. Claycomb's instructions [19] . HL-1 cells (1 × 10 5 ) were seeded onto a 6-well plate and were grown for 48 h in complete media. Before stimulation, cells were washed with PBS and then were incubated with vehicle (control cells), GA (A8301, Sigma, Milan, Italy, at 100 or 250 μg/mL corresponding to ∼1.5 μmol/L or ∼3.7 μmol/L, respectively), and non-glycated recombinant albumin (HSA, A9731, Sigma, Milan, Italy, at 250 μg/mL corresponding to ∼3.7 μmol/L) for 8 or 16 h in Claycomb serum free medium. For secretome analysis, the treatment of the cells for 8 h and 16 h with vehicle or human albumin (GA or non-glycated) was prolonged for additional 24 h after changing the medium with serum-and phenol-free medium [20].
MTT assay
The methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay was based on the protocol first described by Mosmann [21] . Briefly, after treatment for 16 h with GA (100-250 μg/mL) or vehicle in Claycomb serum-free media as specified above, the cells were washed with PBS and incubated in serum-free and phenol-free medium for 24 h. Afterward, cells were incubated for 30 min at 37°C with 0.1 mg/mL of MTT (Sigma-Aldrich, Milan, Italy), dissolved in serum-and phenol-free medium. At the end of the incubation, cells were dissolved in DMSO. Absorbance was recorded at 550 nm using the microplate spectrophotometer system (Mithras LB940, Berthold Technologies, Bad Wildbad, Germany). Data are expressed as absorbance values/μg of proteins.
Cell death analysis
Cytoplasmic histone-complexed DNA fragments (mono-and oligonucleosomes) were quantified as described [22] by using a one-step sandwich immunoassay (Cell death detection ELISA, Roche Diagnostics, Mannheim, Germany), according to the manufacturer's instructions. The data are expressed as absorbance at 405 nm (reference wavelength 490 nm)/μg of proteins.
Label-free mass spectrometry analysis
Secretome samples for proteomic analysis were desalted, concentrated and digested as previously described [20] with minor variations. Briefly, the cell culture media from each condition were collected and cell debris was removed by centrifugation. Then, samples were dialyzed at 4°C using a 3500 molecular weight cut-off dialysis tubing (Spectrum Laboratories, Rancho Dominguez, CA, USA) against 5 mmol/ L NH 4 HCO 3 containing 0.01% EDTA, followed by dialysis against water. After lyophilization, the secreted protein pellets were dissolved in 25 mmol/L NH 4 HCO 3 containing 0.1% RapiGest (Waters Corporation, Milford, MA, USA), sonicated, and centrifuged at 13 000×g for 10 min. Samples (25 μg of protein) were then incubated 15 min at 80°C and reduced with 5 mmol/L DTT at 60°C for 15 min, followed by carbamidomethylation with 10 mmol/L iodoacetamide for 30 min at room temperature in the darkness. Then, 2 μg of sequencing grade trypsin (Promega, Milan, Italy) were added to each sample and incubated overnight at 37°C. After digestion, 2% TFA was added to hydrolyze RapiGest and inactivate trypsin. Tryptic peptides were used for labelfree mass spectrometry analysis. Label-free mass spectrometry analysis, LC-MS E , was performed on a hybrid quadrupole-time of flight mass spectrometer coupled with a nanoUPLC system and equipped with a Trizaic source, as previously detailed [20, 23] .
Gene ontology analysis
Data were analyzed with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING 10.5) database [24] as previously described [25] , to identify enriched gene ontology (GO) terms in the biological process, molecular function or cellular component categories.
Intracellular reactive oxygen species (ROS) formation
Generation of intracellular ROS was measured by the oxidativesensitive fluorescent probe 2′,7′-dichlorofluorescein diacetate (DCF-DA). HL-1 cells were grown in complete media for two days on 96 black-wall clear bottom plates followed by 24 h of starvation in serumfree and phenol-free media. Cells were incubated with 10 μmol/L DCFH-DA (Sigma-Aldrich, Milan, Italy) in serum-free and phenol-free media for 1 h at 37°C in the presence of 100 μmol/L ascorbic acid. At the end of the incubation, cells were washed in PBS and exposed to GA 250 μg/mL, HSA 250 μg/mL or vehicle for the indicated time. The production of ROS was measured by the intensity of DCF emission at 525 nm (excitation 485 nm), in a multifunctional microplate reader Tecan Infinite 200 PRO (TECAN, Milan, Italy). Results are expressed as absolute fluorescence (arbitrary units) of DCF after subtracting blank readings from all measurements.
Western blotting
Cell monolayers were harvested in Laemmli buffer (2% SDS, 10% glycerol and 62.5 mmol/L Tris, pH 6.8) containing a protease inhibitor cocktail (Sigma-Aldrich, Milan, Italy). Cell protein content was measured using the DC Protein Assay (Biorad Laboratories, Milan, Italy). Equal amounts of proteins (specifically 35 μg for the detection of HNEadducts, 15 μg for the detection of carbonylated proteins, and 10 μg for the detection of HSP90 beta), from each condition, were separated on 12% SDS-polyacrylamide gel under reducing conditions in running buffer (25 mmol/L Tris, 3.5 mmol/L SDS, 192 mmol/L glycine) and transferred to nitrocellulose membranes in Transfer buffer with SDS (25 mmol/L Tris, 192 mmol/L glycine, 20% methanol, and 0.02% SDS) as previously described [26] . Transferred proteins were stained with MEMCode staining kit (Thermo Fisher Scientific, Milan, Italy) for loading control. The membranes were incubated with primary antibodies against 4-HNE-adducts (1:3000, Abcam, Cambridge, UK) or HSP90 beta (1:5000, Thermo Fisher Scientific, Milan, Italy), and subsequently with anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5000, Bio-Rad, Milan, Italy).
For the detection of carbonylated proteins, lyophilized pellets were suspended in 6% SDS and extracted proteins were derivatized with 20 mmol/L DNPH (in TFA 20%) for 15 min at room temperature. The DNPH-derivatized samples were then neutralized with 2 mol/L Trizma buffer containing 30% glycerol and 10% 2-β-mercaptoethanol, and the proteins were separated by SDS-PAGE and blotted to nitrocellulose membranes. Immunodetection was carried out using biotinylated anti-DNP antibody (1:5000, Invitrogen, Milan, Italy) and conjugated avidin-HRP (1:1000, Biorad, Milan, Italy) [27] .
The bands were visualized by means of enhanced chemiluminescence (GE Healthcare, Milan, Italy) and analyzed with the QuantityOne software (Bio-Rad Laboratories, Milan, Italy) for densitometric analysis including normalization for total protein loading.
RNA extraction and real-time reverse transcription polymerase chain reaction (RT-PCR)
Total cellular RNA was extracted using the Total RNA purification plus kit (Norgen BioTek, Ontario, Canada) and reverse transcribed at 42°C for 50 min, and at 70°C for 15 min (Bio-Rad Laboratories, Milan, Italy). For 1 μg of total cellular RNA, we used 200 units of reverse transcriptase (RT; SuperScript III, Invitrogen, Life Technologies, Monza, Italy), 3 μg random hexamer primers, 1 mmol/L dNTPs, and 40 units Rnase inhibitor.
Real-time quantitative PCR (qRT-PCR) was carried out to detect Nrf2, IL-6, TNF-α, IL-10, PGC1α, and PGC1β mRNA, with GAPDH mRNA being used for sample normalization. Primers were purchased from Integrated DNA Technologies (Leuven, Belgium) and the primer sequences were: mouse GAPDH sense 5′ CGTGCCGCCTGαAACC 3'; mouse GAPDH antisense: 5′ TGGAAGAGTGGGAGTTGCTGTTG 3'; mouse Nrf2 sense 5′ GATGCTCATGAAATTTGCCTGC 3′ and mouse Nrf2 antisense: 5′ ACAAGCTTCGGTCTGGATCCA 3'. Primers for IL-6 (QT00098875), TNF-α (QT00104006), IL-10 (QT00106169), PGC1α (QT02524242), and PGC1β (QT00125272), were purchased from Qiagen (Milan, Italy). qRT-PCR was carried out as previously described on the iCycler optical system (Bio-Rad Laboratories, Milan, Italy) [28] .
Statistical analysis
Clinical data from healthy subjects (control) and HF patients were analyzed using SAS v9.4 (SAS Institute, Cary, NC, USA) and are expressed as mean ± standard deviation (SD), subdividing HF patients according to NYHA class (III vs IV). Univariate analysis was performed by ANOVA to identify statistically different variables among groups while Pearson correlation was used to identify a possible correlation between GA and clinical variables. General linear model (GLM) was used to highlight the trend of increase of GA with the gravity of the disease, both as univariate analysis and as multivariate analysis taking into consideration differences of age and presence of hypertension.
Data obtained from in vitro experiments were expressed as mean values ± SEM and analyzed with GraphPad Prism v5.03 using ANOVA for repeated measures, followed by Tukey's test (n = the number of individual experiments performed in duplicate or triplicate), after normality assessment by Kolmogorov-Smirnov tests. p values of < 0.05 were considered significant.
Results
Analysis of glycated albumin in heart failure patients
Mass spectrometry analysis of albumin in human plasma samples allowed us to calculate the fraction of GA with respect to all the albumin isoforms (Fig. 1A ). Comparing the percentage of GA between healthy subjects and HF patients, subdivided according to HF severity as inferable from the NYHA class (III vs IV), we observed an increase of GA in the plasma of the patients with respect to the healthy subjects (6.53 ± 0.54% for healthy subjects, 7.38 ± 1.47% for HF class III, and 8.13 ± 0.77% for HF class IV, Table 1 ). The statistical analysis demonstrated that the percentage of GA was significantly higher in the patients' group with the higher degree of HF severity (Fig. 1B) , according to a univariate ANOVA analysis (p = 0.0075) and GLM analysis (p = 0.0022). Considering that age and presence of hypertension correlate with GA and are significantly different among groups, a multivariate GLM analysis was also performed after adjustment for age and hypertension revealing a significant association of GA with HF severity (p = 0.0391). Of note, we detected an inverse correlation between GA and peak VO 2 /Kg (Fig. 1C) , a known index of oxygen consumption previously associated with HF severity [17] .
Analysis of CML levels on the plasma of HF patients and controls did not reveal any significant changes ( Supplementary Fig. 1 ), thus indicating that in our samples early glycation, not advanced glycation, was present (data not shown).
Proteomic analysis of the secretome from HL-1 treated with GA
In order to investigate the effects of GA on HL-1 cardiomyocytes, we stimulated the cells with the purified commercially available GA. To this purpose, we first characterized the glycation sites present in the purified commercially available GA and in the one isolated from plasma of HF patients by means of mass spectrometry (details are available in the Supplementary Material). Results showed that 8 out of 9 glycated residues found in the human albumin from HF patients were also present in the purified commercially available GA ( Supplementary Fig. 2 and Supplementary Table S1 ). Additional modified residues were detected only in the purified commercially available GA, although the majority at a low relative abundance ( Supplementary Table S1 ).
Aiming to elucidate the biological impact of GA on HL-1 cardiomyocytes, we first determined the influence of GA on cell viability and apoptosis. The cells were stimulated with GA (100 or 250 μg/mL) for 16 h and then subjected to MTT assay. As reported in Fig. 2A , cells treated with GA (250 μg/mL) exhibited a slightly decreased in proliferation (−10%, p < 0.05) compared to the control cells. Further, apoptosis was assessed by means of Cell Death Detection ELISA assay, which measures cytosolic histone-associated DNA fragments present in the cell lysates. Results indicated that cell apoptotic responses remained unchanged after GA treatment (Fig. 2B) .
For the proteomic analysis, HL-1 cells were pre-treated for 8 h or 16 h with GA (100 or 250 μg/mL) in serum-free Claycomb medium and then incubated for 24 h, in serum-free phenol-free medium in the absence of GA, in order to collect secreted proteins without the contamination of the exogenously added GA. Then, employing a label-free mass spectrometry based method (LC-MS E ) [20] , we compared the secretome after GA treatment at the two different time points (8 h and 16 h) and identified those proteins that were differently abundant.
This approach allowed us to identify a total of 216 and 246 proteins in cells incubated for 8 h or 16 h, respectively, as reported in Supplementary Tables S2 and S3 . After treatment with GA for 8 h, eight proteins were less abundant after treatment with 250 μg/mL GA, and only one was released at higher extent ( Table 2) . At 16 h, six proteins were more abundant after treatment with 250 μg/mL GA, while eight were more abundant in the secretome of control cells ( Table 3 ).
The lists of differentially abundant proteins were analyzed with STRING for evaluation of protein-protein interactions and gene ontology analysis in order to find out the enriched biological processes. As shown in Fig. 3 , considering only the proteins that were modulated after 8 h, no significantly enriched biological process was detected, while among proteins modulated after 16 h of treatment some biological processes, including response to organic substance and response to stress, were significantly enriched.
Of note, three proteins (Heat shock protein HSP90 beta, Nucleolin and Heat shock protein HSP90 alpha) belonging to these biological processes were commonly modulated at 8 h and 16 h, as shown in the Venn diagram in Fig. 4 .
Thus, in order to verify the proteomic results, we confirmed by immunoblotting that treatment with GA significantly reduced the release of Heat shock protein HSP90 beta (Fig. 5 ). This modulation was not observed when cells were stimulated with non-glycated HSA (250 μg/mL) ( Supplementary Fig. 3A ).
Effects of GA on protein oxidation and lipoxidation
In view of the statistically significant enrichment of the GO term related to response to stress, we next assessed the capacity of GA to cause oxidative damage.
Exposure of HL-1 cells to GA resulted in the rapid intracellular generation of ROS, assessed by DCF fluorescence (Fig. 6 ). When cells were in presence of non-glycated HSA no increase in ROS levels was observed ( Supplementary Fig. 3B ).
Subsequently, we investigated whether GA mediated downstream oxidative damage to proteins. We evaluated, by means of western blot, intracellular 4-hydroxynonenal-protein adducts and carbonylated protein levels, both biomarkers of protein oxidation and lipoxidation. Levels of adducted proteins with 4-hydroxynonenal (4-HNE) after 8 h and 16 h of cell treatment with GA are shown in Fig. 7A and C, and Supplementary Figs. 4B and 4C. Densitometric analysis revealed that 4-HNE-protein adduct levels increased dose-dependently at 8 h, being statistically significant when the cells were incubated with GA (250 μg/ mL) ( Fig. 7B ). 4-HNE-protein adducts formation after 16 h of cell treatment with GA did not change with respect to the control cells ( Fig. 7D) .
Carbonylated protein levels of cells treated with GA were detected after DNPH derivatization of the carbonyl groups using an anti-DNP antibody ( Fig. 8A and C, Supplementary Figs. 4D and 4E ). Densitometric analysis unveiled that cells treated with GA showed a significant increase in protein carbonylation in comparison with control cells at 16 h ( Fig. 8B and D) . Cells treatment with non-glycated HSA (250 μg/ mL) did not show differences in the levels of carbonylated proteins with respect to the control cells ( Supplementary Figs. 3C and 3D) .
Additionally, it was also investigated if GA could modulate mRNA expression levels of nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Our results showed a significant increase of Nrf2 mRNA when the cells were treated with 250 μg/mL GA, either after 8 h and 16 h ( Fig. 9 ). This effect was not observed when the cells were treated with non-glycated HSA ( Supplementary Fig. 3E ).
Effects of GA on inflammation and mitochondrial biogenesis mediators
Further, our results highlighted a significantly enhanced IL-6 mRNA production only after 8 h of treatment with GA (100 or 250 μg/mL) ( Fig. 10A and E) . The levels of IL-6 mRNA were not significantly Fig. 1 . Glycated albumin (GA) in heart failure patients. A) Representative deconvoluted ESI-MS spectrum of albumin from plasma of a HF patient. Arrows indicate the mercaptoalbumin (native HSA), the cysteinylated (Cys-HSA), and the glycated (GA) albumin isoforms characterized by a mass shift of 119 ± 2 and 162 ± 2 Da with respect to the native HSA, respectively. ESI-MS spectra were acquired in positive ion mode and setting a scan range of m/z 1100-1350. B) The percentage of GA with respect to the total amount of albumin has been analyzed by mass spectrometry in healthy subjects (controls) and HF patients divided in NYHA class III and class IV. Observed GA percentage values were 6.53 ± 0.54%, 7.38 ± 1.47%, and 8.13 ± 0.77% for healthy subjects, HF class III, and HF class IV, respectively. Values are represented as mean ± SEM. *p < 0.05 vs controls. C) Correlation between the percentage of GA and peak VO 2 /Kg. HSA, human serum albumin. affected when the cells were treated for 8 h with non-glycated HSA (250 μg/mL) ( Supplementary Fig. 3F ). Additionally, a significant increase of TNF-α mRNA levels was observed in cells treated with GA (250 μg/mL), but not with non-glycated HSA, for 8 h ( Fig. 10B and Supplementary Fig. 3G ). The anti-inflammatory cytokine interleukin-10 (IL-10) mRNA was not detectable even after stimulation with GA (data not shown).
We next investigated the effects of GA on the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha and beta (PGC1α and PGC1β respectively), two genes involved in the mitochondrial biogenesis. As regards PGC1α, no significant modulations were observed either after 8 h or 16 h of treatment ( Fig. 10C and F) . By the contrary, PGC1β mRNA levels raised after 8 h of treatment with GA ( Fig. 10D and G) .
Discussion
In this study, we found an increased amount of glycated albumin, measured by quantitative mass spectrometry, in the plasma of HF patients, and we took advantage of a proteomics-based approach to assess the effects of GA in in vitro cultured cardiomyocytes. Further, a functional interpretation of the identified proteins, obtained by searching the Gene Ontology (GO) annotations for over-represented terms, revealed that GA is a potential mediator of the response to stress.
Among proteins decreased after GA treatment, we found HSP90, one of the most abundant cellular HSPs that contributes intracellularly to In B, proteins associated with the GO term response to stress are colored in blue (p = 0.0229), while proteins associated with the response to organic substances are colored in red (p = 0.000222).
cell survival and protection by regulating the folding and stability of a wide range of key cellular proteins, including survival and apoptotic factors [29] . HSP90 efficiently ameliorates myocardial IR-induce myocardial dysfunction in ischemic condition [30] and exerts an antiapoptotic effect on cardiomyocytes subjected to hypoxia [31] , whereas the inhibition of HSP90 markedly diminishes the protective effects of hypoxic pre-conditioning against prolonged hypoxia/reoxygenationinduced injury in H9C2 cardiac cells [32] . On the other hand, extracellular HSP90 predisposes vascular smooth muscle cells to a pro-inflammatory phenotype by IL-8 elevation in the stressed vasculature [33] . Additionally, the association of extracellular HSP90 with transforming growth factor β receptor I (TGCβRI) at the surface of cardiac fibroblast plasma membrane is critical in collagen production during fibrotic processes [34] . The role of HSPs in the glycated bovine serum albumin mediated effects has been previously observed in cultured β-cells in which a HSP60-correlated signaling pathway was hypothesized to contribute to the AGEs-RAGE axis-induced β-cell hypertrophy and dysfunction under diabetic hyperglycemia [35] .
Nevertheless, there is still limited information with respect to the HSPs extracellular role on cardiomyocytes and their relationship with the pathogenesis of HF.
Moreover, we found that exposure of cardiomyocytes to GA resulted in oxidative modifications, in terms of carbonylation or lipoxidation adducts, of a multitude of cellular proteins. We indeed observed that GA significantly enhances ROS production, which is in agreement with Supplementary Fig. 4A ). *p < 0.05 vs untreated cells. previous works [36] , and modulates the expression of Nrf2, a master transcription factor that becomes upregulated in response to oxidative stress [37] . The observed increase in protein carbonylation and 4-HNEprotein adduct formation can be a downstream effect of the oxidative stress mediated by GA, where excessive ROS may either oxidize proteins directly or modify them indirectly through the adduction of small breakdown products of lipid peroxidation such as 4-HNE [38] . The increase in the levels of 4-HNE modified proteins at 8 h, but not later, is suggestive of their removal by the proteasomal system, as reported by Griesser et al. [39] .
The first evidence of a connection between GA and oxidative stress was the suppression of GA-induced cell apoptosis by antioxidants in bovine retinal pericytes [40] . In macrophages, GA activates ERK-dependent increases in TGF-β1 production, through oxidative stress and NF-κB induction [41] . An accumulation of oxidatively modified proteins, mainly structural proteins (i.e. ACTB and Annexin A2), was observed in human mature adipocytes incubated with GA [42] . Further, GA induces lipid infiltration in mice aorta independently of diabetes and of renin-angiotensin system local modulation by inducing lipid peroxidation and inflammation [43] .
We also analyzed the expression levels of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1 α (PGC-1α) and β (PGC-1 β), which, beyond their role as 'master regulator' of mitochondrial biogenesis, have been identified as inducer of many antioxidant-detoxifying enzymes [44] [45] [46] . Downregulation of PGC-1α causes indeed an increase of intracellular ROS levels and carbonylated proteins and a decrease of antioxidant enzymes [47] . Additionally, mitochondrial activity and ROS scavenging in skeletal muscles of PGC-1β deficient mice can be enhanced by PGC-1β [46] . In our study we observed an early increase in the expression of PGC-1β but not of PGC-1α, suggesting that they cannot completely counteract the pro-oxidant effects of GA.
We also found that GA increased the expression of the pro-inflammatory cytokines IL-6 and TNF-α. Previous studies have indeed shown that GA upregulates several inflammatory mediators through the NF-κB and AP-1 signaling pathways in smooth muscle cells and endothelial cells [48, 49] . Of interest, GA stimulates cell growth and migration in smooth muscle cells and fibroblasts [48, 50] , suggesting that GA may play a role in atherogenesis by inducing both inflammatory mediators in the vessel wall, as well as proliferative and migratory effects. By contrast, in cardiomyocytes GA slightly reduced cell viability thus supporting the hypothesis that GA plays a role in cardiac dysfunction [51] .
In conclusion, this study shows that GA, measured by mass spectrometry, is elevated in the plasma of patients with HF, and it is highest in subjects with the most severe HF, thus expanding previous observations obtained by means of an enzymatic assay [52] . Specifically, Selvin et al. found a significant association of GA with cardiovascular outcomes (new cases of coronary heart disease, ischemic stroke, HF, and deaths), even after adjustment for traditional cardiovascular risk factors, in 11 104 participants with and without diabetes, during two decades of follow-up of in the community-based Atherosclerosis Risk in Communities (ARIC) Study.
Further, the findings that GA exerts pro-inflammatory and pro-oxidant effects on murine HL-1 cardiomyocytes, highlight a causal role in the etiopathogenesis of HF. However, some limitations need to be acknowledged. Indeed, other factors rather than only HF may contribute to increase the GA levels in this population studied. Further, due to the small sample size, we did not study patients with moderate HF or patients at high risk of HF, so that the progressive role of GA in the development of HF is still unknown, albeit the correlation between GA levels and peak VO 2 suggests it. Finally, our results could provide a mechanistic base for a possible use of the new antidiabetic drugs (DPP-4 inhibitors) in non-diabetic HF patients due to their favourable effect in reducing glycated proteins, specifically haemoglobin [53] .
This study also highlights the role of mass spectrometry for the detection and quantitation of specific protein modifications, and contributes to strengthen the value of GA measurement over that of HbA1c which has important limitations: it does not change rapidly in response to changes in treatment, and a number of conditions affect the validity of the test result (eg, anemia, altered red cell lifespan, transfusion, kidney disease, liver disease, and abnormal forms of hemoglobin).
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